Natera Unveils Innovation Roadmap for MRD and Early Cancer Detection
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, presented an exciting update to the investment community during the 43rd annual J.P. Morgan Healthcare Conference. In addition to announcing its preliminary financial results for the fourth quarter and…
Therapeutics Company Tune Raises Over $175M in Series B to Advance Epigenome Editing
Therapeutics Company Tune Raises Over $175M in Series B to Advance Epigenome Editing Tune Therapeutics, a leading company in the field of epigenome editing, today revealed the successful completion of a financing round totaling over $175 million. The funding was…
Alnylam Reports Q4 and Full Year 2024 Revenue and 2025 Guidance
Alnylam Reports Q4 and Full Year 2024 Revenue and 2025 Guidance Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, today announced preliminary global net product revenues for the fourth quarter and full year of 2024, covering…
Hologic Reports Preliminary Revenue Results for Q1 Fiscal 2025
Hologic Reports Preliminary Revenue Results for Q1 Fiscal 2025 Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and diagnostic solutions, today announced its preliminary revenue results for the first quarter of fiscal 2025, which ended on December 28,…
Results: Castle Biosciences Reports Preliminary Q4 and 2024 Performance
Results: Castle Biosciences Reports Preliminary Q4 and 2024 Performance Castle Biosciences, Inc. (Nasdaq: CSTL), a company dedicated to improving patient care through innovative tests, today announced preliminary unaudited performance results for the fourth quarter and full year ending December 31,…
Research Network: N-Power Medicine Acquires Syapse for Oncology
Research Network: N-Power Medicine Acquires Syapse for Oncology N-Power Medicine, a leader in transforming the clinical trial process, has announced the acquisition of Syapse Holdings Inc. (“Syapse”), a trailblazer in precision medicine solutions for community cancer centers. By integrating Syapse…
Gilead and LEO Pharma Partner on Oral STAT6 Program
Gilead and LEO Pharma Partner on Oral STAT6 Program Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today revealed a strategic partnership aimed at fast-tracking the development and commercialization of LEO Pharma’s small molecule oral STAT6 (Signal Transducer and Activator…
Cigna Foundation Grants Support Veterans’ Mental Health and Housing
Cigna Foundation Grants Support Veterans’ Mental Health and Housing The Cigna Group Foundation recently announced the 22 recipients for its inaugural year of a new grant program designed to support veterans’ mental health by focusing on housing stability. The initiative,…
Pfizer’s Sasanlimab + BCG Boosts Event-Free Survival in High-Risk Bladder Cancer
Pfizer’s Sasanlimab + BCG Boosts Event-Free Survival in High-Risk Bladder Cancer Pfizer Inc. (NYSE: PFE) has announced promising topline results from its pivotal Phase 3 CREST trial, which evaluated sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus…
City Therapeutics Teams Up with Bausch + Lomb on RNAi Treatment for Geographic Atrophy
City Therapeutics Teams Up with Bausch + Lomb on RNAi Treatment for Geographic Atrophy City Therapeutics, Inc., a biopharmaceutical leader in RNA interference (RNAi)-based medicine, has announced a strategic collaboration with global eye health leader Bausch + Lomb. The partnership…
Reports Positive Results from SP-624 qEEG and BNA™ Study by Arrivo BioVentures
Reports Positive Results from SP-624 qEEG and BNA™ Study by Arrivo BioVentures Arrivo BioVentures recently reported promising results from its SP-624-103 study, which evaluated the impact of SP-624’s novel epigenetic mechanism on neurological pathways. SP-624, a SIRT6 activator, may represent…
Compass Pathways Sets Price for Underwritten Offering
Compass Pathways Sets Price for Underwritten Offering Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on accelerating access to evidence-based mental health innovations, has announced the pricing of an underwritten offering. This offering includes 24,014,728 American Depositary Shares (ADSs)…